The Effect of Nafarelin Acetate, a Luteinizing-Hormone–Releasing Hormone Agonist, on Benign Prostatic Hyperplasia

New England Journal of Medicine

Volumn 317, Issue 10, 1987, Pages 599-604

  Peters, Craig A ^a   Walsh, Patrick C ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; GONADORELIN; NAFARELIN ACETATE;

BLADDER; BLADDER NECK STENOSIS; CLINICAL ARTICLE; DRUG THERAPY; HUMAN; MALE GENITAL SYSTEM; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; THERAPY;

EID: 0023227737     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM198709033171004     Document Type: Article

References (36)

1. Walsh PC. Human benign prostatic hyperplasia: etiological considerations. In: Kimball FA, Buhl AE, Carter DB, eds. New approaches to the study of benign prostatic hyperplasia: proceedings of the Ninth Brook Lodge Workshop on Problems in Reproductive Physiology, held in Augusta, Michigan, September 26–27, 1983. New York: Alan R. Liss, 1984: 1–25.
2. Hunter J. Observations on certain pans of the animal economy. In: Palmer JF, ed. The complete works of John Hunter. Vol. 4. Philadelphia: Haswell, Barrington, and Haswell, 1841:68.
3. White JW. The results of double castration in hypertrophy of the prostate. Ann Surg 1895; 22: 1–80.
4. Otnes B. Ramm-Whites operasjon: kastrasjon for prostata-hyperplasi. Tidsskr Nor Laegeforen 1986; 106: 301–3.
5. Robinson WJ. Failure of castration to cause atrophy of the prostate. Med Rec 1896; 49: 822.
6. Deming CL, Jenkins RH, Van Wagenen G. Some endocrinological relationships of prostatic hypertrophy: clinical and experimental studies: preliminary report. J Urol 1935; 33: 388–99.
7. Huggins C, Stevens RA. The effect of castration on benign hypertrophy of the prostate in man. J Urol 1940; 43: 705–14.
8. Wendel EF, Brannen GE, Putong PB, Grayhack JT. The effect of orchiectomy and estrogens on benign prostatic hyperplasia. J Urol 1972; 108: 116–9.
9. Geller J, Bora R, Roberts T, Newman H, Lin A, Silva R. Treatment of benign prostatic hypertrophy with hydroxyprogesterone caproate: effect on clinical symptoms, morphology, and endocrine function. JAMA 1965; 193: 121–8.
10. Wolf H, Madsen PO. Treatment of benign prostatic hypertrophy with progestational agents: a preliminary report. J Urol 1968; 99: 780–5.
11. Peirson EL. A study of the effect of stilbestrol therapy on the size of the benignly hypertrophied prostate gland. J Urol 1946; 55: 73–8.
12. Kaufman JJ, Goodwin WE. Hormonal management of the benign obstructing prostate: use of combined androgen-estrogen therapy. J Urol 1959; 81: 165–71.
13. Caine M, Perlberg S, Gordon R. The treatment of benign prostatic hypertrophy with flutamide (SCH 13521): a placebo-controlled study. J Urol 1975; 114: 564–8.
14. Scott WW, Wade JC. Medical treatment of benign nodular prostatic hyperplasia with cyproterone acetate. J Urol 1969; 101: 81–5.
15. Walsh PC. Benign prostatic hyperplasia. In: Walsh PC, Gittes RF, Perlmutter AD, Stamey TA, eds. Campbell's urology. 5th ed. Vol. 2. Baltimore: W.B. Saunders, 1985:1248–65.
16. Scott WW, Coffey DS. Nonsurgical treatment of human benign prostatic hyperplasia. Vitam Horm 1975; 33: 439–65.
17. Blum JJ, Conn PM. Gonadotropin-releasing hormone stimulation of luteinizing hormone release: a ligand–receptor–effector model. Proc Natl Acad Sci USA 1982; 79: 7307–11.
18. Smith WA, Conn PM. GnRH-mediated desensitization of the pituitary gonadotrope is not calcium dependent. Endocrinology 1983; 112: 408–10.
19. Tolis G, Mehta A, Comaru-Schally AM, Schally AV. Suppression of androgen production by D-tryptophan-6-luteinizing hormone-releasing hormone in man. J Clin Invest 1981; 68: 819–22.
20. Watanabe H, Igari D, Tanahashi Y, Harada K, Saitoh M. Measurements of size and weight of prostate by means of transrectal ultrasonotomography. Tohoku J Exp Med 1974; 114: 277–85.
21. Henneberry M, Carter MF, Neiman HL. Estimation of prostatic size by suprapubic ultrasonoeraphy. J Urol 1979; 121: 615–6.
22. Abu-Yousef MM, Narayana AS. Transabdominal ultrasound in the evaluation of prostate size. JCU 1982; 10: 275–8.
23. Chwalla R, Zandanell E. Untersuchungen über die Samenblasengrösse bei Prostatikern, über die diffuse Prostatahyperplasie und die Samenblasenhyperplasie. Urol Int 1958; 7: 199–242.
24. Siroky MB, Olsson CA, Krane RJ. The flow rate nomogram. I. Development. J Urol 1979; 122: 665–8.
25. Siroky The flow rate nomogram. II. Clinical correlation. J Urol 1980; 123: 208–10.
26. Abrams PH, Griffiths DJ. The assessment of prostatic obstruction from urodynamic measurements and from residual urine. Br J Urol 1979; 51: 129–34.
27. Madsen PO, Iversen P. A point system for selecting operative candidates. In: Hinman F Jr, ed. Benign prostatic hypertrophy. New York: Springer-Verlag, 1983:763–5.
28. Abrams PH. Prostatism and prostatectomy: the value of urine flow rate measurement in the preoperative assessment for operation. J Urol 1977; 117: 70–1.
29. Chalkley HW. Method for the quantitative morphologic analysis of tissues. JNCI 1943; 4: 47–53.
30. Weibel R, Kistler GS, Scherle WF. Practical stereological methods for morphometric cytology. J Cell Biol 1966; 30: 23–38.
31. Bartsch G, Müller HR, Oberholzer M, Rohr HP. Light microscopic stereological analysis of the normal human prostate and of benign prostatic hyperplasia. J Urol 1979; 122: 487–91.
32. Burton K. Determination of the DNA concentration with diphenylamine. Methods Enzymol 1968; 12B: 163–6.
33. Frimodt-Møller PC, Jensen KM-E, Iversen P, Madsen PO, Bruskewitz RC. Analysis of presenting symptoms in prostatism. J Urol 1984; 132: 272–6.
34. Franks LM. Benign prostatic hyperplasia: gross and microscopic anatomy. In: Grayhack JT, Wilson JD, Scherbenske MJ, eds. Benign prostatic hyperplasia: a workshop sponsored by the Kidney Disease and Urology Program of the National Institute of Arthritis. Metabolism and Digestive Diseases. Washington, D.C.: Government Printing Office, 1976:63–89. (DHEW publication no. (NIH) 76–1113.)
35. Wenderoth UK, George FW, Wilson JD. The effect of a 5α-reductase inhibitor on androgen-mediated growth of the dog prostate. Endocrinology 1983; 113: 569–73.
36. Brooks JR, Berman C, Garnes D, et al. Prostatic effects induced in dogs by chronic or acute oral administration of 5α-reductase inhibitors. Prostate 1986; 9: 65–75.